Based on a subgroup analysis, in the CheckMate 057 trial, patients with KRAS-mutant lung cancers achieved the greatest OS benefit when comparing immune checkpoint inhibitors (ICIs) with chemotherapy (HR 0.52, 95% CI: 0.29–0.95) [43]. This evidence concerns the gene KRAS and lung carcinoma.